Pharmacokinetic and pharmacodynamic properties of long-acting insulin analogue NN304 in comparison to NPH insulin in humans

Experimental and Clinical Endocrinology and Diabetes

Volumn 108, Issue 2, 2000, Pages 100-105

  Brunner, G A ^a   Sendlhofer, G ^a   Wutte, A ^a   Ellmerer, M ^b   Sogaard B ^c   Siebenhofer, A ^a   Hirschberger, S ^c   Krejs, G J ^a   Pieber, T R ^a  

^a UNIVERSITY OF GRAZ   (Austria)

^b GRAZ UNIVERSITY OF TECHNOLOGY   (Austria)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Insulin analogue; Long acting insulin; NPH

Indexed keywords

GLUCOSE; INSULIN DERIVATIVE; INSULIN DETEMIR; ISOPHANE INSULIN; LONG ACTING DRUG; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG PROTEIN BINDING; GLUCOSE INFUSION; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; CARRIER PROTEINS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HUMANS; INSULIN; INSULIN, ISOPHANE; KINETICS; MALE; PLACEBOS; SERUM ALBUMIN;

EID: 0034011079     PISSN: 09477349     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-5887     Document Type: Article

References (22)

1. Brange J: Insulin preparations.In: Galenics of Insulin: The PhysicoChemical and Pharmaceutical Aspects of Insulin and Insulin Preparations. Springer Verlag, Berlin, pp 17-35, 1987
2. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237: E214-223, 1979
3. Gilbaldi M, Perrier D: Pharmacokinetics.In: Drugs and the Pharmaceutical Sciences. Swarbrick J, Ed. New York, Dekker, Vol. 15, 1982
4. Hallas-Møller K: The Lente insulins. Diabetes 5: 7-14, 1956
5. Havelund S, Kurtzhals P, Jonassen I, Ribel U, Markussen J: The time-action profile of acylated insulins depend on the animal model. Diabetologia 39 (Suppl. 1): A224, 1996
6. Heine RJ, Bilo HJG, Fonk T, van der Veen EA, van der Meer J: Absorption kinetics and action profiles of mixtures of short- and intermediate acting insulins. Diabetologia 27: 558-562, 1984
7. Heinemann L, Heise T, Klepper A, Ampudia J, Bender R, Starke AA: Time-action profiles of the intermediate-acting insulin analogue des(64,65)-human proinsulin. Diabete et Metabolisme 21: 415-419, 1995
8. Heinemann L, Siriha K, Weyer C, Loftager M, Hirschberger S, Heise T: Time-action profile of the soluble, fatty acid acylated long-acting insulin analogue NN304. Diabetic Medicine 16: 332-338, 1999
9. Howey DC, Woodworth JR, Bowsher RR, Revicrgo J: Pharmacokinetic and glucodynamic assessments of N-palmitoyl, LYS(B29) human insulin in healthy volunteers. Diabetologia 40 (Suppl 1): A354, 1997
10. Krayenbühl C, Rosenberg T: Crystalline protamine insulin. Rep Steno Mem Hosp Nord Insulinlab 1: 60-73, 1946
11. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Larsen UD, Ribel U, Markussen J: Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein interaction and correlation between binding affinity and timing of the insulin effect in vivo. J Biochem 312: 725-731, 1995
12. Kurtzhals P, Havelund S, Jonassen I, Kiehr B, Ribel U, Markussen J: Albumin binding and time action of acylated insulins in various species. J Pharm Sci 85(3): 304-308, 1996
13. Markussen J, Havelund S, Kurtzhals P, Andersen AS, Halstrom J, Hasselager E, Larsen UD, Ribel U, Schaffer L, Vad K, Jonassen I: Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 39: 208-288, 1996
14. Mayer PR, Brazzell RK: Application of statistical moment theory to pharmacokinetics. J Clin Pharmacol 29: 481-483, 1988
15. Melvin KD, Hamilton-Wessler M, Ader M, Poulin RA, Moore D, Markussen D: Long acting insulin analogue NN304 has similar transendothelial transport to porcine insulin. Diabetes 46 (Suppl. 1): 164A, 1997
16. Owens DR: Insulin preparations with prolonged effect.In: Owens DR (ed.) Human insulin. Clinical pharmacological studies in normal man. MTP Press Ltd., Falcon House. Lancaster, Englandpp 138-145, 1986
17. Pieber TR, Brunner GA, Schnedl WJ, Schattenberg S, Kaufmann P, Krejs GJ: Evaluation of a structured outpatient education programme for intensive insulin therapy. Diabetes Care 18: 625-630, 1995
18. Ponchner M, Heine RJ, Pernet A, Hanning I, Francis AJ, Cook D, Orskov H, Alberti KGGM: A comparison of the artificial pancreas (glucose controlled insulin infusion system) and a manual technique for assessing insulin sensitivity during euglycaemic clamping. Diabetologia 26: 420-425, 1984
19. Radziuk J, Pye S, Bradley R, Braaten J, Vignati L, Roach P, Bowsher R, DiMarchi R, Chance R: Basal activity profiles of NPH and [N-palmitoyl Lys (B29)] human insulins in subjects with IDDM. Diabetologia 41: 116-120, 1998
20. Ribel U, Hougaard P, Drejer K, Sørensen AR: Equivalent in vivo biological activity of insulin analogues and human insulin despite different in vitro potencies. Diabetes 39: 1033-1039, 1990
21. Veng Petersen P: Mean time parameters in pharmacokinetics: definition, coraputation and clinical implications (part 1). Clin Pharmacokinet 17: 345-366, 1989
22. Veng Petersen P: Mean time parameters in pharmacokinetics: definition, computation and clinical implications (part 2). Clin Pharmacokinet 17: 424-440, 1989